Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
JBIO
$13.88
$
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Next Earnings
2026-02-25
Beta
1.021239
Average Volume
Market Cap
Last Dividend
CIK
0001798749
ISIN
US0080642061
CUSIP
008064206
CEO
Tom Frohlich
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
50
IPO Date
2025-04-29
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Jade Biosciences to Participate in Upcoming Conferences | SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: | GlobeNewsWire | 2026-02-11 07:00:00 |
| Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-16 12:26:03 |
| Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference | JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human study in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027 Third development candidate, JADE301, nominated; currently in preclinical development; Phase 1 clinical trial expected to commence in the first half of 2027 Approximately $336 million of cash, cash equivalents, and investments as of December 31 st , 2025 expected to provide runway into the first half of 2028 Company to present at the 44 th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 a.m. | GlobeNewsWire | 2026-01-05 07:00:00 |
| Jade Biosciences Announces $45 Million Private Placement | SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses. | GlobeNewsWire | 2025-12-15 07:00:00 |
| Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect? | The mean of analysts' price targets for Jade Biosciences, Inc. (JBIO) points to a 65% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | Zacks Investment Research | 2025-12-04 10:56:12 |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|